

A study of guselkumab in participants with fistulizing, perianal Crohn's disease

Submission date 12/05/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 07/11/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 18/06/2025	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Crohn's disease is a chronic inflammatory disease that can affect any part of the digestive tract. It causes inflammation in lining of digestive tract and development of ulcers. A major complication of Crohn's disease are perianal fistulas (infected tunnels develop between skin and digestive tract at end of the latter).

Guselkumab is a medicine that targets interleukin (IL)-23*and blocks it from binding to its receptor (protein that binds to specific molecule). By blocking the effects of IL-23, inflammation is reduced thus preventing disease from worsening.

*Specific protein involved in inflammation.

This study is designed to see if guselkumab is effective and safe for treatment of fistulizing, perianal Crohn's disease.

Who can participate?

Study will include male and female participants 18 years and older with fistulizing, perianal Crohn's disease.

What does the study involve?

The study will be conducted in 3 phases:

1. Screening (Up to 6 weeks)
2. Treatment (Up to 48 weeks): Participants will be randomly (like flip of coin) divided into 3 groups to receive the treatment.

- Group 1: Guselkumab Dose 1 as an injection in vein at the beginning followed by Dose 1 as an injection under skin afterwards.
- Group 2: Guselkumab Dose 1 as an injection in vein at the beginning followed by guselkumab Dose 2 injection under skin afterwards.
- Group 3: Placebo as an injection in vein at the beginning followed by an injection under skin

afterwards. Participants who respond to placebo will continue this and the ones who don't respond will start receiving guselkumab Dose 3 followed by Dose 1 as injection under skin afterwards.

Participants who complete assessment at Week 48 may have option to participate in long-term extension phase and will receive guselkumab until Week 96.

3. LTE Phase (Up to Week 96)

During study visits a variety of tests will be carried out including but not limited to, blood tests, MRI, questionnaires, vital signs, and suicidality assessments. All side effects will be recorded until study ends (Up to 118 weeks).

What are the possible benefits and risks of participating?

There is no established benefit to participants of this study. Based on scientific theory, taking guselkumab may improve fistulizing, perianal Crohn's disease. However, this cannot be guaranteed because guselkumab is still under investigation as a treatment and it is not known whether guselkumab will work.

If participants are put into the placebo treatment group, they will not receive guselkumab until they are not responding to placebo. (Participants who don't respond to placebo, will start receiving guselkumab.)

Participants may experience some benefit from participation in the study that is not due to receiving study drug itself, but due to regular visits and assessments monitoring overall health. Participation may help other people with fistulizing, perianal Crohn's disease in the future.

Participants may have side effects from the drugs or procedures used in this study that may be mild to severe and even life-threatening, and they can vary from person to person. The most common, known risks are getting symptoms such as serious infections and reactivation of latent infections, hypersensitivity reactions, including serious hypersensitivity reactions, liver injury, and malignancy after getting the study drug. There are other, less frequent risks. The participant information sheet and informed consent form, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining the known risks to participating in the study.

Not all possible side effects and risks related to guselkumab are known at this moment. During the study, the sponsor may learn new information about guselkumab. The study doctor will tell participants as soon as possible about any new information that might make them change their mind about being in the study, such as new risks.

To minimize the risk associated with taking part in the study, participants are frequently reviewed for any side effects and other medical events. Participants are educated to report any such events to the study doctor who will provide appropriate medical care. Any serious side effects that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team.

There are no costs to participants to be in the study. The sponsor will pay for the study drug and tests that are part of the study. The participant will receive reasonable reimbursement for study-related costs (e.g., travel/parking costs).

Where is the study run from?
Parexel International (Ireland)

When is the study starting and how long is it expected to run for?
May 2022 to May 2027

Who is funding the study?
Janssen-Cilag Limited (UK)

Who is the main contact?
Dr Kamal Patel, kamal.patel@stgeorges.nhs.uk

Contact information

Type(s)
Scientific

Contact name
Dr Clinical Trials Information

Contact details
Janssen-Cilag International NV
Turnhoutseweg 30
Beerse
Belgium
2340
-
RA-RNDUS-ClnclTrlsEU@its.jnj.com

Type(s)
Principal Investigator

Contact name
Dr Kamal Patel

Contact details
St Georges University Hospitals
Blackshaw Road
Tooting
London
United Kingdom
SW17 0QT
+44 7508471362
kamal.patel@stgeorges.nhs.uk

Additional identifiers

EudraCT/CTIS number
2021-000491-10

IRAS number

1005481

ClinicalTrials.gov number

NCT05347095

Secondary identifying numbers

CNTO1959CRD3005, IRAS 1005481, CPMS 52671

Study information

Scientific Title

A phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn's disease

Acronym

FUZION CD

Study objectives

Main objective:

To evaluate how effective guselkumab is for the treatment of fistulizing, perianal Crohn's disease.

Secondary objectives:

1. To further evaluate how effective guselkumab is for treatment of fistulizing, perianal Crohn's disease.
2. To assess the overall safety of guselkumab.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/07/2022, North West - Liverpool Central Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 2071048016; liverpoolcentral.rec@hra.nhs.uk), ref: 22/NW/0169

Study design

Interventional double blind randomized parallel group placebo controlled trial

Primary study design

Interventional

Secondary study design

Randomised parallel trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Fistulizing Crohn's disease, perianal Crohn's disease

Interventions

Group 1: Guselkumab - Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.

Group 2: Guselkumab - Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.

Group 3: Placebo - Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Guselkumab, placebo

Primary outcome measure

Current primary outcome measure as of 18/06/2025:

1. Percentage of participants who achieve combined fistula remission at week 24. Time frame Week 24
Percentage of participants who achieve combined fistula remission at Week 24 will be reported.
2. Combined fistula remission is defined as 100 percentage (%) closure of all treated external openings without development of new fistulas or abscesses and without any drainage by the external openings [occurring spontaneously or after gentle finger compression] and absence of collections greater than (>) 2 centimeters (cm) of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the magnetic resonance imaging [MRI] results.

Previous primary outcome measure:

Percentage of participants who achieve combined fistula remission at week 24. Time frame Week 24

Percentage of participants who achieve combined fistula remission at Week 24 will be reported.

Secondary outcome measures

Current secondary outcome measures as of 18/06/2025:

1. Percentage of participants who achieve combined fistula remission at week 48. Time frame Week 48

Percentage of participants who achieve combined fistula remission at Week 48 will be reported.

2. Percentage of participants who achieve clinically assessed fistula remission at week 24. Time frame Week 24

Percentage of participants who achieve clinically assessed fistula remission will be reported.

Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

3. Percentage of participants who achieve radiological fistula remission based on radiological findings assessed by MRI at week 24. Time frame Week 24

Percentage of participants who achieve radiological fistula remission based on radiological findings assessed by MRI will be reported.

Radiological remission is defined as absence of collections >2 cm of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the MRI results.

4. Percentage of participants who achieve clinically assessed fistula response at week 24. Time frame Week 24

Percentage of participants who achieve clinically assessed fistula response at Week 24 will be reported. Clinically assessed fistula response is defined as a greater than or equal to (\geq) 50% reduction from baseline in number of open or draining perianal fistulas.

5. Percentage of Participants who Achieve Clinically Assessed Fistula Response at Week 12. Time frame Week 12

Percentage of participants who achieve clinically assessed fistula response at Week 12 will be reported. Clinically assessed fistula response is defined as \geq 50% reduction from baseline in number of open or draining perianal fistulas.

6. Change from Baseline in Crohn's Disease Activity Index (CDAI) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in CDAI by visit over time will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily basis.

7. Percentage of Participants who Achieve Clinical Remission (CDAI less than [$<$] 150) by Visit Over Time Through Week 48 Among Participants with CDAI Greater than ($>$) 150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve clinical remission (CDAI $<$ 150) by visit over time through Week 48 among participants with CDAI $>$ 150 at baseline will be reported.

CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain [AP]/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily

basis.

8. Percentage of Participants who Achieve a Clinical Response by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve a clinical response by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Clinical response is defined greater than or equal to (\geq) 100-point reduction from baseline in CDAI, or CDAI <150.

9. Percentage of Participants who Achieve Steroid-free Clinical Remission by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve steroid-free clinical remission by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Steroid-free clinical remission is defined as CDAI <150 and not receiving corticosteroids by visit over time through Week 48 among participants with CDAI >150 at baseline.

10. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response Among Participants With CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula response among participants with CDAI >220 at baseline at baseline will be reported. Clinical response is defined \geq 100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula response is defined as \geq 50% reduction from baseline in number of open or draining perianal fistulas.

11. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission Among Participants With CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission among participants with CDAI >220 at baseline at will be reported. Clinical remission is defined as CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

12. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Remission Among Participants with CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula remission among participants with CDAI >220 at baseline will be reported. Clinical response is defined \geq 100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

13. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response Among Participants with CDAI >220 at Baseline at Week 24 and 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula response among participants with CDAI >220 at baseline will be reported. Clinically assessed fistula response is defined as \geq 50% reduction from baseline in number of open or draining perianal fistulas.

14. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinical response is defined \geq 100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula response is defined \geq 50% reduction from baseline in number of open or draining perianal fistulas.

15. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed

Fistula Remission at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula remission at Week 24 and Week 48 will be reported. Clinical response is defined ≥ 100 -point reduction from baseline in CDAI, or CDAI < 150 . Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

16. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinically assessed fistula response is defined as $\geq 50\%$ reduction from baseline in number of open or draining perianal fistulas.

17. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

18. Change from Baseline in Perianal Disease Activity Index (PDAI) Overall Score, Discharge Score, and Pain Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in PDAI overall score, discharge score, and pain score by visit over time through Week 48 will be reported. The PDAI is a scoring system to evaluate the severity of perianal lesion associated with Crohn's disease. It includes the following 5 items: (a) Discharge; (0=no discharge to 4= Gross fecal soiling) (b) Pain; (0=no activity to 4= severe pain, severe limitation) (c) Restriction of sexual activity; (0=no perianal disease/skin tags to 4= unable to engage in sexual activity) (d) Type of perianal disease; (0=no perianal disease/skin tags to 4=Anal sphincter ulceration or fistulae with significant undermining ok skin) and (e) Degree of induration; (0=no induration to 4=gross fluctuance/abscess. Higher scores indicate more severe or active disease.

19. Percentage of Participants who Achieve Clinically Assessed Fistula Response by Visit Over Time Through Week 48. Time frame Through Week 48

Percentage of participants with clinically assessed fistula response by visit over time through Week 48 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

20. Percentage of Participants who Achieve Clinically Assessed Fistula Remission by Visit over Time Through Week 48. Time frame Through Week 48

Percentage of participants with clinically assessed fistula remission by visit over through Week 48 time will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

21. Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among the Participants who Achieve Clinical Fistula Remission at Week 24. Time frame Week 48

Percentage of participants who achieve clinically assessed fistula remission at Week 48 among the participants who achieve clinical fistula remission at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

22. Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among Those who Achieve Fistula Remission or Response at Week 24. Time frame Week 48

Percentage of participants achieving clinically assessed fistula remission at Week 48 among those who achieve fistula remission or response (defined either by clinical or radiological

assessment) at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

23. Time to Clinical Fistula Remission. Time frame Up to Week 96

Time to clinical fistula remission will be reported. Clinical fistula remission is defined as 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by the external openings (occurring spontaneously or after gentle finger compression).

24. Percentage of Participants who Achieve Radiological Fistula Predominantly Fibrotic Status for all Existent Fistulas Assessed by MRI at Week 24 and Week 48. Time frame Week 24 and Week 48

Percentage of participants who achieve radiological fistula predominantly fibrotic status for all existent fistulas assessed by MRI at Week 24 and Week 48 will be reported.

25. Percentage of participants who Achieve Radiological Remission Based on Radiological Findings Assessed by MRI at Week 48. Time frame Week 48

Percentage of participants with radiological remission based on radiological findings assessed by MRI at Week 48 will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.

26. Percentage of Participants who Achieve Radiological Remission Assessed by MRI at Week 48 Among the Participants who Achieve Radiological Remission at Week 24. Time frame Week 48

Percentage of participants who achieve radiological remission assessed by MRI at Week 48 among the participants who achieve radiological remission at Week 24 will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.

27. Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission at Week 48 Among the Participants who Achieve Combined Clinical and Radiological Fistula Remission at Week 24. Time frame Week 48

Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve combined clinical and radiological fistula remission at Week 24.

28. Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission as Week 48 Among the Participants with Clinical Fistula Response at Week 24. Time frame Week 48

Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve clinical fistula response at Week 24 will be reported.

29. Percentage of Participants with Proctitis at Week 48 Among Participants with MRI confirmed Proctitis at Baseline. Time frame Week 48

Percentage of participants with proctitis at Week 48 among participants with MRI-confirmed proctitis at baseline will be reported. Proctitis is defined as the inflammation of the lining of the rectum.

30. Change from Baseline in Magnetic Resonance Novel Index for Fistula imaging in Crohn's disease (MAGNIFI-CD) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48
Change from baseline in MAGNIFI-CD by visit over time through Week 48 will be reported. The MAGNIFI-CD is based on MRI assessment of 6 items including number of fistula tracts, fistula length, hyperintensity of primary tract on post[1]contrast T1-weighted images, dominant feature, extension, and inflammatory mass. The total MAGNIFI-CD score ranges from 0 (no disease activity) to 25 (severe disease activity). It assesses the MRI data and determines perianal fistulizing CD activity with improved operating characteristics compared to the Van Assche Index (VAI) and the modified VAI (mVAI).

31. Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by Visit Over

Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by visit over time through Week 48 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate patient reported outcomes (PROs) across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

32. Change From Baseline in Functional Assessment of Chronic Illness Therapyfatigue (FACIT-F) Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change From baseline in FACIT-F Score at Week 48 will be reported. The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists of 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores [4 - score]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

33. Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Crohn's Disease (WPAI:CD) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48
Change from baseline in WPAI:CD by visit over time through Week 48 will be reported. The WPAI:CD assesses the impact of CD on work and activity during the past 7 days. The specificity of WPAI:CD is achieved by replacing "health problems" in the general health version of the WPAI with "CD." It consists of 6 questions, which elicit the following information: employment status; hours missed due to CD; hours missed due to other reasons; hours actually worked; the degree to which CD affected productivity while working from 0 (no effect) to 10 (maximum impairment); and the degree to which CD affected regular activities (from 0- 10). The sum of worktime missed and impairment at work yields the overall work impairment (productivity loss) score; scores are expressed as percent of impairment/productivity loss, with higher scores indicating greater impairment.

34. Change from Baseline in Quality-of-life as Assessed by European Quality-of-Life Five Dimension Five Level Scale (EQ5D-5L) Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in quality-of-life (EQ5D-5L) score by visit over time through Week 48 will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

35. Change from Baseline in the Jorge-Wexner Score by Visit Over Time Through Week 48. Time frame Baseline through to Week 48

Change from baseline in the Jorge-Wexner score by visit over time through Week 48 will be reported. The Jorge-Wexner scoring system cross-tabulates frequencies and different anal incontinence presentations.

36. Change from Baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by Visit Over Time Through Week 48. Time frame Baseline through to Week 48

Change from baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by visit over time through Week 48 will be reported. The IBD-DI consists of 28 items that evaluate the 5 domains of overall health, body function, body structures, activity participation and environmental factors. Each item response is graded from 0 to 4 for each area evaluated (0 = very good; 1 = Good; 2 = medium; 3 = Bad; 4 = Very bad). The final composite score representative of the overall degree of disability ranging from -80 (maximum degree of disability) to 22 (no disability).

37. Number of Participants with Treatment-emergent Adverse Events (TEAEs). Time frame up to week 48. An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

38. Number of Participants with Treatment-emergent Serious Adverse Events (TESAEs). Time frame up to week 48. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TESAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.

Previous secondary outcome measures:

1. Percentage of participants who achieve combined fistula remission at week 48. Time frame Week 48

Percentage of participants who achieve combined fistula remission at Week 48 will be reported.

2. Percentage of participants who achieve clinically assessed fistula remission at week 24. Time frame Week 24

Percentage of participants who achieve clinically assessed fistula remission will be reported.

3. Percentage of participants who achieve radiological fistula remission based on radiological findings assessed by MRI at week 24. Time frame Week 24

Percentage of participants who achieve radiological fistula remission based on radiological findings assessed by MRI will be reported.

4. Percentage of participants who achieve clinically assessed fistula response at week 24. Time frame Week 24

Percentage of participants who achieve clinically assessed fistula response at Week 24 will be reported. Clinically assessed fistula response is defined as closure of at least 50 percent (%) of all external openings that were draining at baseline.

5. Percentage of Participants who Achieve Clinically Assessed Fistula Response at Week 12. Time frame Week 12

Percentage of participants who achieve clinically assessed fistula response at Week 12 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

6. Change from Baseline in Crohn's Disease Activity Index (CDAI) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in CDAI by visit over time will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily basis.

7. Percentage of Participants who Achieve Clinical Remission (CDAI less than [$<$] 150) by Visit Over Time Through Week 48 Among Participants with CDAI Greater than ($>$) 150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve clinical remission (CDAI $<$ 150) by visit over time through Week 48 among participants with CDAI $>$ 150 at baseline will be reported.

CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain [AP]/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being with scores ranging from 0 to approximately 600. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on a daily basis.

8. Percentage of Participants who Achieve a Clinical Response by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve a clinical response by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Clinical response is defined greater than or equal to (\geq) 100-point reduction from baseline in CDAI, or CDAI <150.

9. Percentage of Participants who Achieve Steroid-free Clinical Remission by Visit Over Time Through Week 48 Among Participants with CDAI >150 at Baseline. Time frame Through Week 48

Percentage of participants who achieve steroid-free clinical remission by visit over time through Week 48 among participants with CDAI >150 at baseline will be reported. Steroid-free clinical remission is defined as CDAI <150 and not receiving corticosteroids by visit over time through Week 48 among participants with CDAI >150 at baseline.

10. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response Among Participants With CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula response among participants with CDAI >220 at baseline at baseline will be reported. Clinical response is defined \geq 100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

11. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission Among Participants With CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission among participants with CDAI >220 at baseline at will be reported. Clinical remission is defined as CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

12. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Remission Among Participants with CDAI >220 at Baseline at Week 24 and 48. Time frame Week 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula remission among participants with CDAI >220 at baseline will be reported. Clinical response is defined \geq 100-point reduction from baseline in CDAI, or CDAI <150. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

13. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response Among Participants with CDAI >220 at Baseline at Week 24 and 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula response among participants with CDAI >220 at baseline will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

14. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Response at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinical response is defined ≥ 100 -point reduction from baseline in CDAI, or CDAI < 150 . Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

15. Percentage of Participants who Achieve Combined Clinical Response and Clinically Assessed Fistula Remission at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical response and clinically assessed fistula remission at Week 24 and Week 48 will be reported. Clinical response is defined ≥ 100 -point reduction from baseline in CDAI, or CDAI < 150 . Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

16. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Response at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula response at Week 24 and Week 48 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

17. Percentage of Participants who Achieve Combined Clinical Remission and Clinically Assessed Fistula Remission at Week 24 and Week 48. Time frame 24 and Week 48

Percentage of participants who achieve combined clinical remission and clinically assessed fistula remission will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

18. Change from Baseline in Perianal Disease Activity Index (PDAI) Overall Score, Discharge Score, and Pain Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in PDAI overall score, discharge score, and pain score by visit over time through Week 48 will be reported. The PDAI is a scoring system to evaluate the severity of perianal lesion associated with Crohn's disease. It includes the following 5 items: (a) Discharge; (0=no discharge to 4= Gross fecal soiling) (b) Pain; (0=no activity to 4= severe pain, severe limitation) (c) Restriction of sexual activity;(0=no perianal disease/skin tags to 4= unable to engage in sexual activity) (d) Type of perianal disease; (0=no perianal disease/skin tags to 4=Anal sphincter ulceration or fistulae with significant undermining ok skin) and (e) Degree of induration; (0=no induration to 4=gross fluctuance/abscess. Higher scores indicate more severe or active disease.

19. Percentage of Participants who Achieve Clinically Assessed Fistula Response by Visit Over Time Through Week 48. Time frame Through Week 48

Percentage of participants with clinically assessed fistula response by visit over time through Week 48 will be reported. Clinically assessed fistula response is defined as closure of at least 50% of all external openings that were draining at baseline.

20. Percentage of Participants who Achieve Clinically Assessed Fistula Remission by Visit over Time Through Week 48. Time frame Through Week 48

Percentage of participants with clinically assessed fistula remission by visit over through Week 48 time will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

21. Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among the Participants who Achieve Clinical Fistula Remission at Week 24. Time frame Week 48

Percentage of participants who achieve clinically assessed fistula remission at Week 48 among the participants who achieve clinical fistula remission at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings,

occurring spontaneously or after gentle finger compression.

22. Percentage of Participants who Achieve Clinically Assessed Fistula Remission at Week 48 Among Those who Achieve Fistula Remission or Response at Week 24. Time frame Week 48
Percentage of participants achieving clinically assessed fistula remission at Week 48 among those who achieve fistula remission or response (defined either by clinical or radiological assessment) at Week 24 will be reported. Clinically assessed fistula remission is defined as 100% closure of all treated external openings, without development of new fistulas or abscesses and without any drainage by the external openings, occurring spontaneously or after gentle finger compression.

23. Time to Clinical Fistula Remission. Time frame Up to Week 96

Time to clinical fistula remission will be reported. Clinical fistula remission is defined as 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by the external openings (occurring spontaneously or after gentle finger compression).

24. Percentage of Participants who Achieve Radiological Fistula Predominantly Fibrotic Status for all Existent Fistulas Assessed by MRI at Week 24 and Week 48. Time frame Week 24 and Week 48

Percentage of participants who achieve radiological fistula predominantly fibrotic status for all existent fistulas assessed by MRI at Week 24 and Week 48 will be reported.

25. Percentage of participants who Achieve Radiological Remission Based on Radiological Findings Assessed by MRI at Week 48. Time frame Week 48

Percentage of participants with radiological remission based on radiological findings assessed by MRI at Week 48 will be reported. Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.

26. Percentage of Participants who Achieve Radiological Remission Assessed by MRI at Week 48 Among the Participants who Achieve Radiological Remission at Week 24. Time frame Week 48

Percentage of participants who achieve radiological remission assessed by MRI at Week 48 among the participants who achieve radiological remission at Week 24 will be reported.

Radiological remission is defined as absence of collections >2 cm of the perianal fistulas, confirmed by a blinded central review of the MRI results.

27. Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission at Week 48 Among the Participants who Achieve Combined Clinical and Radiological Fistula Remission at Week 24. Time frame Week 48

Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve combined clinical and radiological fistula remission at Week 24.

28. Percentage of Participants who Achieve Combined Clinically Assessed and Radiological Fistula Remission as Week 48 Among the Participants with Clinical Fistula Response at Week 24. Time frame Week 48

Percentage of participants who achieve combined clinically assessed and radiological (assessed by MRI) fistula remission at Week 48 among the participants who achieve clinical fistula response at Week 24 will be reported.

29. Percentage of Participants with Proctitis at Week 48 Among Participants with MRI confirmed Proctitis at Baseline. Time frame Week 48

Percentage of participants with proctitis at Week 48 among participants with MRI-confirmed proctitis at baseline will be reported. Proctitis is defined as the inflammation of the lining of the rectum.

30. Change from Baseline in Magnetic Resonance Novel Index for Fistula imaging in Crohn's disease (MAGNIFI-CD) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in MAGNIFI-CD by visit over time through Week 48 will be reported. The MAGNIFI-CD is based on MRI assessment of 6 items including number of fistula tracts, fistula length, hyperintensity of primary tract on post[1]contrast T1-weighted images, dominant

feature, extension, and inflammatory mass. The total MAGNIFI-CD score ranges from 0 (no disease activity) to 25 (severe disease activity). It assesses the MRI data and determines perianal fistulizing CD activity with improved operating characteristics compared to the Van Assche Index (VAI) and the modified VAI (mVAI).

31. Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) by visit over time through Week 48 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate patient reported outcomes (PROs) across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

32. Change From Baseline in Functional Assessment of Chronic Illness Therapyfatigue (FACIT-F) Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change From baseline in FACIT-F Score at Week 48 will be reported. The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists of 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score is calculated as the sum of the 13 item scores (reserved scores [4 - score]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

33. Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Crohn's Disease (WPAI:CD) by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in WPAI:CD by visit over time through Week 48 will be reported. The WPAI:CD assesses the impact of CD on work and activity during the past 7 days. The specificity of WPAI:CD is achieved by replacing "health problems" in the general health version of the WPAI with "CD." It consists of 6 questions, which elicit the following information: employment status; hours missed due to CD; hours missed due to other reasons; hours actually worked; the degree to which CD affected productivity while working from 0 (no effect) to 10 (maximum impairment); and the degree to which CD affected regular activities (from 0- 10). The sum of worktime missed and impairment at work yields the overall work impairment (productivity loss) score; scores are expressed as percent of impairment/productivity loss, with higher scores indicating greater impairment.

34. Change from Baseline in Quality-of-life as Assessed by European Quality-of-Life Five Dimension Five Level Scale (EQ5D-5L) Score by Visit Over Time Through Week 48. Time frame Baseline up to Week 48

Change from baseline in quality-of-life (EQ5D-5L) score by visit over time through Week 48 will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

35. Change from Baseline in the Jorge-Wexner Score by Visit Over Time Through Week 48. Time frame Baseline through to Week 48

Change from baseline in the Jorge-Wexner score by visit over time through Week 48 will be reported. The Jorge-Wexner scoring system cross-tabulates frequencies and different anal incontinence presentations.

36. Change from Baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by Visit Over Time Through Week 48. Time frame Baseline through to Week 48

Change from baseline in the Inflammatory Bowel Disease-Disability Index (IBD-DI) by visit over time through Week 48 will be reported. The IBD-DI consists of 28 items that evaluate the 5

domains of overall health, body function, body structures, activity participation and environmental factors. Each item response is graded from 0 to 4 for each area evaluated (0 = very good; 1 = Good; 2 = medium; 3 = Bad; 4 = Very bad). The final composite score representative of the overall degree of disability ranging from -80 (maximum degree of disability) to 22 (no disability).

Overall study start date

29/04/2022

Completion date

17/05/2027

Eligibility

Key inclusion criteria

1. Must have a diagnosis of Crohn's disease with a minimum duration of at least 3 months
2. Has at least one active draining perianal fistula as a complication of Crohn's disease, confirmed by screening magnetic resonance imaging (MRI) results
3. Is naïve to biologics, or demonstrated inadequate response or intolerance to conventional therapies or approved biologic therapies for Crohn's Disease (CD)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

280

Key exclusion criteria

Current exclusion criteria as of 18/06/2025:

1. Has a very severe luminal disease activity
 2. History of or concurrent rectovaginal fistulas (other types of concurrent fistula should be confirmed with the sponsor), rectal and/or anal stenosis, stoma or functioning ostomy (include all current stoma types abscess or collections which are not properly drained) colonic mucosal dysplasia or pre-cancerous lesions that have not been removed, demyelinating disease, or systemic lupus erythematosus
 3. Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery or preclude fistula evaluation
 4. Any medical contraindications preventing study participation
 5. Has a history of ongoing, chronic or recurrent enteral or systemic infectious disease
-

Previous exclusion criteria:

1. Has a very severe luminal disease activity
2. History of or concurrent rectovaginal fistulas, rectal and/or anal stenosis or other active complications of perianal disease
3. Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery or preclude fistula evaluation
4. Any medical contraindications preventing study participation
5. Has a history of ongoing, chronic or recurrent enteral or systemic infectious disease

Date of first enrolment

29/04/2022

Date of final enrolment

12/02/2025

Locations

Countries of recruitment

Australia

Belgium

Canada

Egypt

England

France

Germany

Greece

Hungary

Israel

Italy

Japan

Jordan

Lebanon

Netherlands

Northern Ireland

Poland

Portugal

Russian Federation

Saudi Arabia

Spain

Sweden

Taiwan

Türkiye

Ukraine

United Kingdom

Study participating centre

St Georges Hospital

Blackshaw Road

London

United Kingdom

SW17 0QT

Study participating centre

Fairfield General Hospital

Fairfield General Hospital

Rochdale Old Road

Bury

United Kingdom

BL9 7TD

Study participating centre

Royal Victoria Infirmary

Queen Victoria Road

Newcastle upon Tyne

United Kingdom

NE1 4LP

Study participating centre

Guy's & St Thomas Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Study participating centre
Hull Royal Infirmary
Anlaby Road
Hull
United Kingdom
HU3 2JZ

Study participating centre
Ulster Hospital
Upper Newtownards Rd
Dundonald
Belfast
United Kingdom
BT16 1RH

Study participating centre
Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
United Kingdom
B15 2GW

Study participating centre
St Marks Hospital
Watford Road
Harrow
United Kingdom
HA1 3UJ

Sponsor information

Organisation

Janssen-Cilag International NV

Sponsor details

Turnhoutseweg 30

Beerse

Belgium

2340

-

RA-RNDUS-ClnclTrlsEU@its.jnj.com

Sponsor type

Industry

Funder(s)

Funder type

Industry

Funder Name

Janssen-Cilag Limited

Results and Publications

Publication and dissemination plan

Publication on website

Coded study data will be shared via secure Sponsor systems. Data sharing will be in accordance with current data privacy legislation and restricted to authorised parties with the necessary confidentiality agreements in place.

Intention to publish date

01/09/2027

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[HRA research summary](#)

28/06/2023

No

No